Amgen secures FDA approval for LUMAKRAS in KRAS G12C-mutated lung cancer treatment
In a significant development for cancer treatment, Amgen has achieved accelerated approval from the U.S. Food and Drug Administration (FDA) for its drug LUMAKRAS (sotorasib), ... Read More
Amgen secures breakthrough therapy designation for sotorasib in China
Amgen has achieved a major milestone in the global development of its investigational KRAS G12C inhibitor, sotorasib, with the National Medical Products Administration (NMPA) in ... Read More